Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Plos Medicine|September 7, 2019
Development of new TB regimens: Harmonizing trial design, product registration requirements, and public health guidanceChristian Lienhardt, Andrew A Vernon, Marco Cavaleri, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 9, 2016
Factors Associated With Noncompletion of Latent Tuberculosis Infection Treatment: Experience From the PREVENT TB Trial in the United States and CanadaRuth N Moro, Andrey S Borisov, Jussi Saukkonen, et al.
Frontiers in Public Health|February 25, 2025
Health inequities among persons with disabilities: a global scoping reviewEmre Umucu, Andrew A Vernon, Deyu Pan, et al.
JAMA Pediatrics|January 13, 2015
Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazidM Elsa Villarino, Nigel A Scott, Stephen E Weis, et al.
Plos Medicine|February 28, 2020
Advances in clinical trial design: Weaving tomorrow's TB treatmentsChristian Lienhardt, Andrew Nunn, Richard Chaisson, et al.
American Journal of Preventive Medicine|June 19, 2018
Isoniazid-Rifapentine for Latent Tuberculosis Infection: A Systematic Review and Meta-analysisGibril J Njie, Sapna Bamrah Morris, Rachel Yelk Woodruff, et al.
AIDS (London, England)|June 1, 2016
Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected personsTimothy R Sterling, Nigel A Scott, Jose M Miro, et al.
Annals of the American Thoracic Society|March 20, 2013
The association between symptoms and microbiologically defined response to tuberculosis treatmentCraig M Hales, Charles M Heilig, Richard Chaisson, et al.
The Lancet. Respiratory Medicine|March 26, 2023
Completion, safety, and efficacy of tuberculosis preventive treatment regimens containing rifampicin or rifapentine: an individual patient data network meta-analysisNicholas Winters, Robert Belknap, Andrea Benedetti, et al.
American Journal of Respiratory and Critical Care Medicine|September 6, 2005
Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosisIan M Rosenthal, Kathy Williams, Sandeep Tyagi, et al.
Pageof 2